5-Sulfonyl-benzimidazoles as selective CB2 agonists-Part 2

Bioorganic and Medicinal Chemistry Letters

Volumn 22, Issue 1, 2012, Pages 547-552

  Gijsen, Harrie J M ^a   De Cleyn, Michel A J ^a   Surkyn, Michel ^a   Van Lommen, Guy R E ^a,b   Verbist, Bie M P ^a,c   Nijsen, Marjoleen J M A ^a,d   Meert, Theo ^a   Wauwe, Jean Van ^a   Aerssens, Jeroen ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b Galapagos ^*  (Belgium)

^c GHENT UNIVERSITY   (Belgium)

^d ABBOTT GMBH AND CO KG   (Germany)

Author keywords

Benzimidazole; Cannabinoid receptor; CB2 agonist

Indexed keywords

5 SULFONYL BENZIMIDAZOLE DERIVATIVE; BENZIMIDAZOLE DERIVATIVE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID 2 RECEPTOR AGONIST; MORPHINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SOLUBILITY; DRUG STABILITY; HUMAN; HUMAN CELL; IN VIVO STUDY; MULTIPLE SCLEROSIS; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; STRUCTURE ACTIVITY RELATION; SYMPTOM;

ANIMALS; BENZIMIDAZOLES; BRAIN; DRUG DESIGN; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; INFLAMMATION; MICE; MODELS, CHEMICAL; MULTIPLE SCLEROSIS; NEURALGIA; RATS; RECEPTOR, CANNABINOID, CB2; STRUCTURE-ACTIVITY RELATIONSHIP; TIME FACTORS;

EID: 84655162746     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.10.091     Document Type: Article

References (21)

1. A.C. Howlett, F. Barth, T.I. Bonner, G. Cabral, P. Casellas, W.A. Devane, C.C. Felder, M. Herkenham, K. Mackie, B.R. Martin, R. Mechoulam, and R.G. Pertwee Pharmacol. Rev. 54 2002 161
2. V. De Marzo Nat. Rev. Drug Disc. 7 2008 438
3. J. Guindon, and A.G. Hohmann Br. J. Pharmacol. 153 2008 319
4. M. Beltramo Mini Rev. Med. Chem. 9 2009 11
5. G.T. Whiteside, G.P. Lee, and K.J. Valenzo Curr. Med. Chem. 14 2007 917
6. B.W. Trotter, K.K. Nanda, C.S. Burgey, C.M. Potteiger, J.Z. Deng, A.I. Green, J.C. Hartnett, N.R. Kett, Z. Wu, D.A. Henze, K. Della Penna, R. Desai, M.D. Leitl, W. Lemaire, R.B. White, S. Yeh, M.O. Urban, S.A. Kane, G.D. Hartman, and M.T. Bilodeau Bioorg. Med. Chem. Lett. 21 2011 2354
7. P.J. Manley, A. Zartman, D.V. Paone, C.S. Burgey, D.A. Henze, K. Della Penna, R. Desai, M.D. Leitl, W. Lemaire, R.B. White, S. Yeh, M.O. Urban, S.A. Kane, G.D. Hartman, M.T. Bilodeau, and B.W. Trotter Bioorg. Med. Chem. Lett. 21 2011 2359
8. B.M.P. Verbist, M.A.J. De Cleyn, M. Surkyn, E. Fraiponts, J. Aerssens, M.J.M.A. Nijsen, and H.J.M. Gijsen Bioorg. Med. Chem. Lett. 18 2008 2574
9. G.A. Thakur, R. Tichkule, S. Bajaj, and A. Makriyannis Expert Opin. Ther. Pat. 19 2009 1647
10. D. Pagé, M.-C. Brochu, H. Yang, W. Brown, S. St.-Onge, E. Martin, and D. Salois Lett. Drug Des. Discov. 3 2006 298
11. T. Ryckmans, M.P. Edwards, V.A. Horne, A.M. Correia, D.R. Owen, L.R. Thompson, I. Tran, M.F. Tutt, and T. Young Bioorg. Med. Chem. Lett. 19 2009 4406
12. C. Watson, D.R. Owen, D. Harding, K. Kon-I, M.L. Lewis, H.J. Mason, M. Matsumizu, T. Mukaiyama, M. Rodriguez-Lens, A. Shima, M. Takeuchi, I. Tran, and T. Young Bioorg. Med. Chem. Lett. 21 2011 4284
13. N. Jain, and S.H. Yalkowsky J. Pharm. Sci. 90 2001 234
14. All compounds tested in this Letter were shown to be full CB2 agonists in our assays. For experimental procedures of the assays, see the Supplementary data of ref
15. T. Itoh, and T. Mase Org. Lett. 24 2004 4587
16. R.G. Pertwee Br. J. Pharmacol. 46 1972 753
17. T.F. Meert, and H. Vermeirsch Pharmacol. Biochem. Be. 80 2005 309
18. G.J. Bennett, and Y.K. Xie Pain 33 1988 87
19. T. Dowdall, I. Robinson, and T.F. Meert Pharmacol. Biochem. Be. 80 2005 93
20. For experimental details, see M. Buntinx, B. Hermans, J. Goossens, D. Moechars, R.A.H.J. Gilissen, J. Doyon, S. Boeckx, E. Coesemans, G. Van Lommen, and J.P. Van Wauwe J. Pharmacol. Exp. Ther. 327 2008 1
21. F. Docagne, L. Mestre, F. Loría, M. Hernangómez, F. Correa, and C. Guaza Expert Opin. Ther. Tar. 12 2008 185